| 000 | 01759 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517235640.0 | ||
| 264 | 0 | _c20190911 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a1744-8042 | ||
| 024 | 7 |
_a10.2217/pgs-2018-0095 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaagdenberg, Hedy | |
| 245 | 0 | 0 |
_aEffects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients. _h[electronic resource] |
| 260 |
_bPharmacogenomics _c10 2018 |
||
| 300 |
_a1195-1202 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2C9 _xgenetics |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPharmacogenetics _xmethods |
| 650 | 0 | 4 |
_aPhenprocoumon _xadministration & dosage |
| 650 | 0 | 4 |
_aPolymorphism, Single Nucleotide _xgenetics |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aVitamin K Epoxide Reductases _xgenetics |
| 700 | 1 | _aBierings, Marc B | |
| 700 | 1 | _avan Ommen, C Heleen | |
| 700 | 1 | _avan der Meer, Felix Jm | |
| 700 | 1 | _aAppel, Inge M | |
| 700 | 1 | _aTamminga, Rienk Yj | |
| 700 | 1 | _aCessie, Saskia le | |
| 700 | 1 | _aSwen, Jesse J | |
| 700 | 1 | _ader Straaten, Tahar van | |
| 700 | 1 | _aBoer, Anthonius de | |
| 700 | 1 | _aMaitland-van der Zee, Anke H | |
| 773 | 0 |
_tPharmacogenomics _gvol. 19 _gno. 15 _gp. 1195-1202 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/pgs-2018-0095 _zAvailable from publisher's website |
| 999 |
_c28827650 _d28827650 |
||